On March 26, 2025 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") reported that an abstract regarding IPH4502, its novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4, has been selected for the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2025, taking place April 25-30 in Chicago, Illinois (Press release, Innate Pharma, MAR 26, 2025, View Source [SID1234651496]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition, Jonathan Dickinson, CEO of Innate Parma, will present in a showcase session at the AACR (Free AACR Whitepaper) Oncology Industry Partnering Event, to give an update on Innate’s pipeline and strategy.

Presentation details

AACR 2025 ANNUAL MEETING

IPH4502, a differentiated Nectin-4 exatecan antibody-drug conjugate

Abstract Number: 5443

Session Type: Poster session

Session Category: Experimental and Molecular Therapeutics

Session Title: Antibody-Based Cancer Therapeutics 3

Session Date/Time: Tuesday Apr 29, 2025 2:00 PM – 5:00 PM

More information can be found on the AACR (Free AACR Whitepaper) website.

AACR ONCOLOGY INDUSTRY PARTNERING EVENT

Showcase Session 2 | W192

Presenter: Jonathan Dickinson, Chief Executive Officer

Date and Time: Thursday Apr 24, 2025 4:50 PM

Location: McCormick Place Convention Center West Building, Chicago, Illinois

More information can be found on the AACR (Free AACR Whitepaper) Oncology Industry Partnering Event website.

About IPH4502

IPH4502 is a novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) conjugated to exatecan targeting Nectin-4, a cell adhesion molecule that is overexpressed in several types of solid tumors, such as urothelial carcinoma, breast cancer, non-small cell lung cancer or gastro-intestinal tract cancer.

IPH4502 is currently investigated in a Phase 1 trial in advanced solid tumors. The Phase 1 trial includes a dose escalation part 1 and a dose optimization part 2 and will assess the safety, tolerability, and preliminary efficacy of IPH4502 in different solid tumors known to express Nectin-4, including but not limited to urothelial carcinoma, non-small cell lung, breast, ovarian, gastric, esophageal, and colorectal cancers. The study plans to enroll approximately 105 patients.

In preclinical models, IPH4502 demonstrates strong bystander killing effect, and efficient internalization, enabling a potent anti-tumor activity in models with various Nectin-4 expression levels. Additionally, IPH4502 shows efficacy in models resistant to MMAE-ADC. These results support its potential for development beyond UC and in cancer patients treated with MMAE-based ADCs.

On March 26, 2025 AbbVie (NYSE: ABBV) reported that new data from its early oncology research will be showcased across multiple presentations at the upcoming American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, April 25-30, 2025 (Press release, AbbVie, MAR 26, 2025, View Source [SID1234651481]). Presentations include data from novel investigational molecules, ABBV-969 and ABBV-514, across a range of hard-to-treat tumor types.1,2 Additionally, new insights on treatment resistance and novel biomarker identification based on real-world-data analyses are to be presented.3,4,5

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"As we seek to advance innovative therapies for people living with difficult-to-treat cancers, our early-stage oncology research helps lay the scientific foundation for future innovation that may address profound unmet needs that many patients experience," said Theodora S. Ross, M.D., Ph.D., vice president, early oncology research and development, AbbVie. "By harnessing the latest scientific breakthroughs in translational research, we are advancing novel therapeutic approaches such as ABBV-969 and ABBV-514, aiming to improve cancer care for patients worldwide."

Data on ABBV-969, a novel, dual-targeted ADC, with a proprietary, cytotoxic topoisomerase 1 inhibitor (Top1i) payload will be presented in an oral presentation at the meeting.1 ABBV-969 is designed to target tumor cells expressing STEAP1 and/or PSMA antigens.1 Prostate cancer cells may overexpress STEAP1, PSMA or both, and their expression is associated with tumor growth and survival.1 ABBV-969 is currently in a Phase 1 clinical trial for men with metastatic castration-resistant prostate cancer (mCRPC) (NCT06318273).6

Data from AbbVie’s immuno-oncology platform highlight the potential of a novel CCR8-targeting antibody, ABBV-514, in driving anti-tumor immunity.2 CCR8 is a promising target due to its enhanced expression on tumor-infiltrating regulatory T cells (Tregs) and a higher prevalence of these CCR8+ Tregs is associated with poor clinical outcomes in several solid tumor types.2 Preclinical data show that ABBV-514 depletes CCR8+ Tregs inside the tumor and has strong monotherapy activity in a variety of in vivo tumor models, including models that are insensitive to anti-PD-1 treatment.2 ABBV-514 is currently being evaluated in a Phase 1 clinical trial in non-small cell lung cancer (NSCLC), head and neck cancer and other solid tumors, both as a monotherapy and in combination with budigalimab, a PD-1-blocking antibody (NCT05005403).2,7,8

Additional presentations at the AACR (Free AACR Whitepaper) annual meeting will include real-world-data analyses in two key areas of cancer research – treatment resistance and biomarker discovery:

An analysis to characterize the overlap of folate receptor alpha (FRa) expression, a biomarker found in 90 percent of ovarian cancers, with other biomarkers that could potentially help support the development of novel precision medicines.4,9,10 This study provides new insights that could aid treatment matching for patients and inform treatment sequencing and combination therapy options.4
A new study that employed multi-omics approaches to real-world-data analysis, to identify clinical features and molecular mechanisms of long-term response and acquired resistance to immunotherapy in non-small cell lung cancer.3
Data showcasing a novel approach for investigating relationships between germline variants, cancer patient prognosis and treatment responses, using electronic health record-linked genomics data across a range of solid tumor types.5 The study shows that certain germline variants may serve as predictive biomarkers and help advance precision medicine R&D efforts.5
Further information on AbbVie clinical trials is available at View Source

Additional details on key presentations at AACR (Free AACR Whitepaper) are available below and the full AACR (Free AACR Whitepaper) Annual Meeting 2025 abstracts are available here.

Title

Date/Time

Session

Abstract number

ABBV-969: A first-in-class dual-targeting
PSMA-STEAP1 drug conjugate for the
treatment of metastatic castrate-resistant
prostate cancer

April 27, 1:45 –

2:00 PM CT

Oral Presentation

Session: New Drugs on the Horizon: Part 1

ND03

Investigating clinical features and
molecular mechanisms of long-term
response and acquired resistance to
immunotherapy in non-small cell lung
cancer by applying real-world-data

April 28, 2:00 –
5:00 PM CT

Poster

Poster Board 15

Session: Real-World Data and Real-World Evidence: Clinico-Genomics

3395

ABBV-514: an afucosylated CCR8
specific antibody that targets and
eliminates key immunosuppressive
tumor regulatory T cells

April 29, 2:00 –
5:00 PM CT

Poster

Poster Board 20

Session: Therapeutic Antibodies,

Including Engineered

Antibodies 2

6025

Characterizing spatial expression
patterns and prevalence of folate
receptor alpha in relation to other
existing and emerging ovarian cancer
biomarkers

April 29, 2:00 –
5:00 PM CT

Poster

Poster Board 2

Session: Predictive Biomarkers 6 /Diagnostic Biomarkers 3

5910

Identifying cancer germline variants
associated with patient prognosis and
response by applying clinico-genomics
data

April 30, 09:00 AM –
12:00 PM CT

Poster

Poster Board 19

Session: Genomic Profiling of Tumors 3

6638

ABBV-969 and ABBV-514 are investigational medicines and are not approved by any health authority worldwide. Their safety and efficacy are under evaluation as part of ongoing clinical studies.

About ABBV-969
ABBV-969 is an investigational, novel antibody-drug conjugate (ADC) targeting prostate-specific membrane antigen (PSMA) and six transmembrane epithelial antigen of the prostate 1 (STEAP1), being investigated to treat metastatic castration-resistant prostate cancer (mCRPC).1,6 ABBV-969 was designed using a dual variable domain immunoglobulin (DVD-Ig) with a proprietary topoisomerase-1 (Top1) inhibitor linker-drug format.1

About ABBV-514
ABBV-514 is an investigational anti-chemokine C-C motif receptor 8 (CCR8) antibody that is being investigated for the treatment of relapsed non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) both as a monotherapy and in combination with a PD-1 inhibitor.

On March 26, 2025 SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, reported it will present new data from two of its antibody-drug conjugate (ADC) programs for the treatment of solid tumors, showcasing advancements in its innovative pipeline (Press release, SOTIO, MAR 26, 2025, View Source [SID1234651497]). The presentations will take place at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in Chicago, IL from April 25-30, 2025.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SOT106 is being developed for the treatment of patients with sarcomas and other LRRC15-positive tumors. The oral presentation at AACR (Free AACR Whitepaper) will feature new preclinical in vitro and in vivo data. SOT106 targets leucine-rich repeat containing protein 15 (LRRC15), a protein that is commonly overexpressed in mesenchymal malignancies.

SOT109 is being developed for the treatment of colorectal cancer and other gastrointestinal cancers. It targets cadherin-17 (CDH17), a protein homogenously overexpressed in more than 90% of colorectal cancers. The poster presentation at AACR (Free AACR Whitepaper) will showcase preclinical data on the efficacy and safety of SOT109 across various models.

Presentation details are as follows:

Oral Presentation Title: "SOT106, a novel best-in-class antibody-drug conjugate targeting LRRC15, to treat sarcomas and other advanced solid cancers"
Abstract Number: 1164
Session: Experimental and Molecular Therapeutics / Antibody-Based Cancer Therapeutic Agents
Presenting Author: Michaela Fojtu
Date & Time: April 27, 2025, 3:00 p.m. – 5:00 p.m. CT

Poster Title: "Preclinical safety and efficacy of SOT109, an antibody-drug conjugate targeting Cadherin 17 (CDH17) for the treatment of colorectal and other gastrointestinal tract tumors"
Abstract Number: 5469
Session: Experimental and Molecular Therapeutics
Presenting Author: Nataliia Kalynovska
Date & Time: April 29, 2025, 2:00 p.m. – 5:00 p.m. CT
Location: Poster Section 15, Board Number 27

Presentation materials will be made available here after presentations at AACR (Free AACR Whitepaper) conclude.

On March 26, 2025 Bayer and Suzhou Puhe BioPharma Co.,Ltd., a clinical-stage biotechnology company, reported that they have entered into a global license agreement for Puhe BioPharma’s oral, small molecule PRMT5 inhibitor that selectively targets MTAP-deleted tumors (Press release, Bayer, MAR 26, 2025, View Source [SID1234655501]). Under the agreement, Bayer obtains an exclusive worldwide license to develop, manufacture and commercialize the MTA-cooperative PRMT5 inhibitor. Bayer has enrolled the first participant in a Phase I first-in-human dose escalation study investigating MTA-cooperative PRMT5 inhibitor under the development name BAY 3713372 for the treatment of MTAP-deleted solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are looking forward to explore the potential of the PRMT5 inhibitor, which could improve outcomes for patients with MTAP-deleted tumors who often have a poor prognosis," said Juergen Eckhardt, M.D., Head of Business Development and Licensing at Bayer’s Pharmaceuticals Division. "The highly selective targeting of cancer cells while sparing healthy cells, based on the innovative mechanism of action is very promising. This will support our mission to build one of the most transformative and differentiated precision oncology pipelines in the industry."

"We see great potential in MTA-cooperative PRMT5 inhibitors in treating MTAP-deleted tumors. Our MTA-cooperative PRMT5 inhibitor, PH020, now named BAY 3713372, has demonstrated competitive selectivity for PRMT5 bound to MTA and activity in preclinical studies, as well as brain penetration capabilities," said Yongqi Guo, CEO of Puhe BioPharma. "We are excited to partner with Bayer, a global leader in the field of life sciences, to advance our PRMT5 inhibitor into the clinic. Together with Bayer, we look forward to bringing this therapeutic option to patients worldwide."

PRMT5 (protein arginine methyltransferase 5) and a specific gene called MTAP (metabolic enzyme 5’-deoxy-5′-methylthioadenosine phosphorylase) play important roles in cell metabolism and are critical for cell survival. MTAP deletions, which occur in approximately 10 to 30 percent of all cancers1, lead to elevated levels of MTA in tumor cells and BAY 3713372 is designed to bind the PRMT5-MTA complex thus specifically exploiting tumor vulnerability.

"Loss of the MTAP gene occurs in a variety of tumor types, including those with few treatment options and poor prognosis, such as pancreatic cancer and glioblastoma," said Dominik Ruettinger, M.D., Ph.D., Global Head of Research and Early Development for Oncology at Bayer’s Pharmaceuticals Division. "We look forward to advancing this program as we are driven by our ambition to develop innovative medicines that improve and extend the lives of cancer patients we serve, focusing on areas of high unmet medical need."

Financial terms are not disclosed.

About BAY 3713372 (MTA-cooperative PRMT5 inhibitor)
BAY 3713372 is an investigational agent and has not been approved by any health authority for use in any country, for any indication. It is an oral, potent selective MTA-cooperative PRMT5 inhibitor being evaluated as a potential new targeted treatment option for patients with MTAP-deleted solid tumors. BAY 3713372 has unique characteristics including brain penetrance, which allows targeting of central nervous system (CNS) metastases and primary brain tumors.

Protein arginine N-methyltransferase 5 (PRMT5) plays a crucial role in modifying proteins that control the cell cycle. The metabolic enzyme 5’-deoxy-5′-methylthioadenosine phosphorylase (MTAP) is involved in the methionine salvage pathway which recycles methionine from methylthioadenosine (MTA).This targeted approach takes advantage of the unique relationship between MTA and PRMT5, creating a specific vulnerability that can be exploited to effectively treat MTAP deficient cancer cells.

About the clinical phase I study
BAY 3713372 is investigated in a global Phase I first-in-human dose escalation study in patients with MTAP-deleted solid tumors. The clinical program aims to evaluate the safety, tolerability and pharmacokinetics, pharmacodynamics and preliminary clinical activity of BAY 3713372, a novel cancer cell specific PRMT5 inhibitor.

On March 25, 2025 Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, reported that it will present preclinical data for its novel HER3 ADC, EO-1022, in a late-breaking poster presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2025, being held April 25-30 in Chicago, Illinois (Press release, Elevation Oncology, MAR 25, 2025, View Source [SID1234651424]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

EO-1022 is an antibody drug conjugate (ADC) containing seribantumab, a fully human IgG2 anti-HER3 monoclonal antibody (mAb), which is site-specifically conjugated at glycan to the monomethyl auristatin E (MMAE) payload with a drug-to-antibody ratio (DAR) of 4. Elevation Oncology designed EO-1022, leveraging the advanced site-specific conjugation technology platform licensed from Synaffix B.V. Elevation Oncology is developing EO-1022 for the treatment of solid tumors that express HER3, including breast cancer and non-small cell lung cancer, and expects to file an IND application in 2026.

"We are eager to share the first preclinical data for EO-1022 at the AACR (Free AACR Whitepaper) Annual Meeting," said Joseph Ferra, President and Chief Executive Officer of Elevation Oncology. "With EO-1022, we are combining the most advanced site-specific conjugation technology platform with the clinically validated MMAE payload, which is widely used across ADC programs but has yet to be introduced into a HER3-targeting ADC in the clinic. We believe this unique combination will enable us to provide a new treatment option to patients with HER3-expressing solid tumors, including those who are refractory to other HER3-targeting agents in development. We look forward to advancing EO-1022 into clinical development next year."

Details of the poster presentation at AACR (Free AACR Whitepaper) 2025 are as follows:

Title: Preclinical discovery and characterization of EO-1022, a site-specific glycan-conjugated anti-HER3 vc-MMAE ADC for treating solid tumors

Abstract Presentation Number: LB004
Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 1
Session Date and Time: Sunday, April 27, from 2 p.m. to 5 p.m. CT (3 p.m. to 6 p.m. ET)
Location: Poster Section 50
The late-breaking abstract will become available on the AACR (Free AACR Whitepaper) website beginning at 12:00 noon CT (1:00 p.m. ET) on April 25, 2025, and published in an online-only supplement to Cancer Research.

About EO-1022

Elevation Oncology is developing EO-1022, a potentially differentiated HER3 ADC for the treatment of HER3-expressing solid tumors, including breast cancer and non-small cell lung cancer. EO-1022 consists of seribantumab, a fully human IgG2 anti-HER3 antibody, site-specifically conjugated at glycan to the MMAE payload with a DAR of 4. It leverages seribantumab’s desirable internalization properties and advanced site-specific ADC technology which makes possible the use of the potent cytotoxic MMAE payload. Elevation Oncology expects to file an IND application in 2026.